1
|
Bi J, Witt E, McGovern MK, Cafi AB, Rosenstock LL, Pearson AB, Brown TJ, Karasic TB, Absler LC, Machkanti S, Boyce H, Gallo D, Becker SL, Ishida K, Jenkins J, Hayward A, Scheiflinger A, Bodeker KL, Kumar R, Shaw SK, Jabbour SK, Lira VA, Henry MD, Tift MS, Otterbein LE, Traverso G, Byrne JD. Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers. Adv Sci (Weinh) 2024; 11:e2308346. [PMID: 38084435 PMCID: PMC10916612 DOI: 10.1002/advs.202308346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 11/30/2023] [Indexed: 01/22/2024]
Abstract
Modulation of autophagy, specifically its inhibition, stands to transform the capacity to effectively treat a broad range of cancers. However, the clinical efficacy of autophagy inhibitors has been inconsistent. To delineate clinical and epidemiological features associated with autophagy inhibition and a positive oncological clinical response, a retrospective analysis of patients is conducted treated with hydroxychloroquine, a known autophagy inhibitor. A direct correlation between smoking status and inhibition of autophagy with hydroxychloroquine is identified. Recognizing that smoking is associated with elevated circulating levels of carbon monoxide (CO), it is hypothesized that supplemental CO can amplify autophagy inhibition. A novel, gas-entrapping material containing CO in a pre-clinical model is applied and demonstrated that CO can dramatically increase the cytotoxicity of autophagy inhibitors and significantly inhibit the growth of tumors when used in combination. These data support the notion that safe, therapeutic levels of CO can markedly enhance the efficacy of autophagy inhibitors, opening a promising new frontier in the quest to improve cancer therapies.
Collapse
|
2
|
Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Carpenter EL, Nathanson K, Domchek SM, Reiss KA. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib. Clin Cancer Res 2023; 29:5207-5216. [PMID: 37486343 PMCID: PMC10806928 DOI: 10.1158/1078-0432.ccr-23-1467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/13/2023] [Accepted: 07/20/2023] [Indexed: 07/25/2023]
Abstract
PURPOSE PARP inhibitors (PARPi) provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi resistance and optimal post-PARPi therapeutic strategies are poorly characterized. EXPERIMENTAL DESIGN We collected paired cell-free DNA samples and post-PARPi clinical data on 42 patients with advanced, platinum-sensitive pancreatic cancer who were treated with maintenance rucaparib on NCT03140670, of whom 32 developed progressive disease. RESULTS Peripherally detected, acquired BRCA or PALB2 reversion variants were uncommon (5/30; 16.6%) in patients who progressed on rucaparib. Reversions were significantly associated with rapid resistance to PARPi treatment (median PFS, 3.7 vs. 12.5 months; P = 0.001) and poor overall survival (median OS, 6.2 vs. 23.0 months; P < 0.0001). All patients with reversions received rechallenge with platinum-based chemotherapy following PARPi progression and experienced faster progression on this therapy than those without reversion variants (real-world time-to-treatment discontinuation, 2.4 vs. 5.8 months; P = 0.004). Of the patients who progressed on PARPi and received further chemotherapy, the OS from initiation of second-line therapy was significantly lower in those with reversion variants than in those without (5.5 vs. 12.0 months, P = 0.002). Finally, high levels of tumor shedding were independently associated with poor outcomes in patients who received rucaparib. CONCLUSIONS Acquired reversion variants were uncommon but detrimental in a population of patients with advanced BRCA- or PALB2-related pancreatic ductal adenocarcinoma who received maintenance rucaparib. Reversion variants led to rapid progression on PARPi, rapid failure of subsequent platinum-based treatment, and poor OS of patients. The identification of such variants in the blood may have both predictive and prognostic value. See related commentary by Tsang and Gallinger, p. 5005.
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania
| | | | - Jacob E Till
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | | | | | - Ryan Hood
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Mark H O'Hara
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Ursina Teitelbaum
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Thomas B Karasic
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Charles Schneider
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Erica L Carpenter
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Katherine Nathanson
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Susan M Domchek
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Kim A Reiss
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
3
|
Brown TJ, Reiss KA, O'Hara MH. Advancements in Systemic Therapy for Pancreatic Cancer. Am Soc Clin Oncol Educ Book 2023; 43:e397082. [PMID: 37192430 DOI: 10.1200/edbk_397082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Outcomes for patients with advanced pancreatic cancer have improved in the past 12 years, mainly because of progress made in systemic therapies. New treatment strategies for advanced pancreatic cancer include switch maintenance with cytotoxic therapies, induction maintenance, and the utilization of targeted agents for patients with actionable variants, as well as ongoing development of cytotoxic regimens, such as NALIRIFOX. The activity of immunotherapy has been disappointing to date, but novel combinations and identifying appropriate patient populations may further unlock its potential.
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA
| | - Kim A Reiss
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA
| | - Mark H O'Hara
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
4
|
Brown TJ, Barrett N, Meng H, Ricciotti E, McDonnell C, Dancis A, Qualtieri J, FitzGerald GA, Cotter M, Babushok DV. Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia. Blood 2023; 141:1553-1559. [PMID: 36574346 PMCID: PMC10082374 DOI: 10.1182/blood.2022018667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 11/22/2022] [Accepted: 12/04/2022] [Indexed: 12/28/2022] Open
Abstract
Advances in genomic diagnostics hold promise for improved care of rare hematologic diseases. Here, we describe a novel targeted therapeutic approach for Ghosal hematodiaphyseal dysplasia, an autosomal recessive disease characterized by severe normocytic anemia and bone abnormalities due to loss-of-function mutations in thromboxane A synthase 1 (TBXAS1). TBXAS1 metabolizes prostaglandin H2 (PGH2), a cyclooxygenase (COX) product of arachidonic acid, into thromboxane A2. Loss-of-function mutations in TBXAS result in an increase in PGH2 availability for other PG synthases. The current treatment for Ghosal hematodiaphyseal dysplasia syndrome consists of corticosteroids. We hypothesize that nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX-1 and COX-2, could ameliorate the effects of TBXAS1 loss and improve hematologic function by reducing prostaglandin formation. We treated 2 patients with Ghosal hematodiaphyseal dysplasia syndrome, an adult and a child, with standard doses of NSAIDs (aspirin or ibuprofen). Both patients had rapid improvements concerning hematologic parameters and inflammatory markers without adverse events. Mass spectrometry analysis demonstrated that urinary PG metabolites were increased along with proinflammatory lipoxygenase (LOX) products 5-hydroxyeicosatetraenoic acid and leukotriene E4. Our data show that NSAIDs at standard doses surprisingly reduced both COX and LOX products, leading to the resolution of cytopenia, and should be considered for first-line treatment for Ghosal hematodiaphyseal dysplasia syndrome.
Collapse
Affiliation(s)
- Timothy J. Brown
- Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Neil Barrett
- Paediatric Haematology, Children's Health Ireland at Temple Street/Crumlin, Dublin, Ireland
| | - Hu Meng
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Emanuela Ricciotti
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Ciara McDonnell
- Paediatric Endocrinology, Children's Health Ireland at Temple Street/Crumlin and Discipline of Paediatrics, University of Dublin Trinity College Dublin, Dublin, Ireland
| | - Andrew Dancis
- Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Julianne Qualtieri
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Garret A. FitzGerald
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Melanie Cotter
- Paediatric Haematology, Children's Health Ireland at Temple Street/Crumlin, Dublin, Ireland
| | - Daria V. Babushok
- Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- Comprehensive Bone Marrow Failure Center, Children’s Hospital of Philadelphia, Philadelphia, PA
| |
Collapse
|
5
|
Brown TJ, Yablonovitch A, Yen J, Kiedrowski LA, Carpenter EL, Nathanson K, Domchek SM, Reiss KA. The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.4_suppl.734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
734 Background: Maintenance PARP inhibition (PARPi) extends progression-free survival and improves quality of life for patients (pts) with advanced, platinum-sensitive pancreatic cancer (PC) and BRCA or PALB2 variants. However, most will experience progression. PARPi resistance mechanisms are poorly defined in PC. Cell-free (cf)DNA analysis can detect some known classes of resistance mechanisms, like reversion mutations, and other potentially prognostic and predictive genomic features. Methods: Pts with advanced, platinum-sensitive pancreatic cancer and pathogenic germline or somatic BRCA1, BRCA2, or PALB2 variants were treated with maintenance rucaparib on clinical trial. cfDNA was collected at baseline and progression and analyzed with the GuardantOMNI 500-gene liquid biopsy. Time to event analysis was performed from index date of enrollment until endpoint (PFS, OS, and PFS2). Associations were tested by the log-rank test with adjustment. Results: The trial enrolled 42 pts, of whom 31 have progressed. cfDNA was available for 41 pts at baseline and 30 pts at progression; 88% had baseline detectable cfDNA. Two pts had baseline reversion mutations, 5 had new reversion mutations at progression. Of 21 pts who had tissue NGS, 17 pts had a KRAS variant in the tumor, 12 of whom had detectable cfDNA at either baseline or progression. Of the 41 patients with cfDNA samples, 10 pts had baseline KRAS mutations detected in plasma; an additional 10 pts had a detectable plasma KRAS mutation at progression. Outcomes are shown. Of those who had progressed, pts with acquired reversion mutations had shorter OS (p<0.001) and PFS (p = 0.018) on rucaparib than those without reversion mutations. Of those who received chemo after progression (n=23), PFS2 was shorter for pts with acquired reversions compared to those with no reversions (p = 0.038). KRAS mutation detection at baseline was observed with higher overall somatic allele fraction in cfDNA and a trend toward shorter PFS and OS. Conclusions: Acquired reversion mutations were infrequent but associated with worse outcomes. Other causes of resistance may be dominant. Detection of KRAS mutation in the peripheral blood may be associated with disease burden and clinical outcome. [Table: see text]
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | | | | | | | | | | | - Susan M. Domchek
- University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA
| | | |
Collapse
|
6
|
Brown TJ, Minn AJ, Carpenter EL, Ben-Josef E, Karasic TB. A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.4_suppl.tps626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
TPS626 Background: Systemic therapy with atezolizumab and bevacizumab (atezo/bev) has improved outcomes for advanced HCC, but results in objective responses in fewer than 30% of patients. Stereotactic body radiotherapy (SBRT) is currently used for small HCC tumors that do not require systemic therapy but has also been shown in a number of clinical trials of other solid tumors to enhance the anti-cancer immune response. Of particular interest, our prior experience with SBRT in a 17Gy fraction has demonstrated the ability to restore sensitivity to immunotherapy in advanced solid tumors, even those previously refractory to immunotherapy. We hypothesize that repeated high dose fractions of radiation will act as an immune booster and will improve on outcomes of patients with advanced HCC. Since the combination of SBRT and atezo/bev has not yet been tested prospectively in patients with HCC, and because bevacizumab is a known radiosensitizer, we are conducting a phase I trial to evaluate the safety of repeated SBRT doses. Methods: This is a single-site phase I clinical trial utilizing a Rolling 6 design to determine the safety of 1, 2, or 3 doses of SBRT fractions in combination with atezo/bev. Up to 18 total patients will be enrolled (n=6 per cohort). Patients must be naïve to systemic therapy with Child-Pugh A or B liver function, at least one lesion amenable to radiation, and a measurable lesion that will not receive radiation. Patients with uncontrolled ascites or hepatic encephalopathy are excluded. Atezo/bev is administered at the standard doses every 21 days. SBRT will start 1 week after the first infusion of this combination. Patients will receive 1, 2, or 3 17Gy fractions of SBRT at 4-week intervals (cohorts 2 and 3 only). Patients will undergo serial collections of circulating cell-free DNA (ccfDNA), methylated DNA, and peripheral blood mononuclear cells to investigate the application of these markers as a predictor of response. Following completion of SBRT, patients will continue with atezo/bev until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint is the proportion of patients experiencing dose-limiting toxicities (grade 3 or higher radiation-related toxicities graded by the Common Terminology Criteria for Adverse Events, Version 5). Secondary endpoints are overall survival, progression-free survival, objective response rate, duration of response, and toxicity rates. Enrollment began 9/2022 and complete accrual is expected by June 2024. NCT05488522. Clinical trial information: NCT05488522 .
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Andy J Minn
- University of Pennsylvania, Philadelphia, PA
| | | | | | | |
Collapse
|
7
|
Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX. Impact of etiology of hepatocellular carcinoma on treatment outcomes in a real-world database. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.4_suppl.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
508 Background: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Systemic therapy with combination atezolizumab and bevacizumab (A/B) is the new treatment standard; yet fewer than 30% experience treatment response. The etiology of HCC (viral, alcohol, or NASH) and its impact on treatment response is unknown. Thus, we sought to determine the impact of etiology on survival outcomes of patients treated with A/B. Methods: This study used the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Patients with HCC receiving first-line A/B after January 1, 2020 were eligible for inclusion. We used a validated algorithm to adjudicate cohort by likely etiology (viral, alcohol and NASH). The primary outcome was median real-world overall survival (OS), defined from initial receipt of A/B until death or censored at last receipt of A/B by etiology. The secondary outcome was real-world time to treatment discontinuation (TTD -a validated surrogate that approximates progression-free survival) defined as time from initial receipt of A/B to progression, death, or treatment discontinuation for more than 120 days or censored at last clinical contact by etiology. The Kaplan-Meier method, Cox proportional hazards model and the log-rank test was used to test for differences between etiologies. Results: In total, 429 eligible HCC patients were included (n=216, 50.3% Viral; n=68, 15.8% Alcohol; n=145, 33.8%, NASH). In the total cohort, median OS was 9.4 months (95% CI 7.1-10.9) and median TTD was 5.7 months (5.0-7.0); by etiology, OS medians were 10.1 (7.2-14.0), 9.8 (6.1-13.9), 7.5 (5.3-11.0) months, and TTD medians were 6.1 (5.0-8.0), 5.8 (3.7-7.8), and 5.5 (2.6-7.0) months, for Viral-HCC, Alcohol-HCC, and NASH-HCC respectively. No significant difference in the hazard of death or TTD by etiology were observed in the unadjusted or adjusted Cox regression analyses (see table). The multivariate model included age, ECOG performance status, receipt of prior locoregional therapy, albumin-bilirubin (ALBI) grade, and baseline aspartate aminotransferase. Conclusions: In this large cohort study of US patients with HCC, we did not identify a significant association between etiology and survival or time to treatment discontinuation outcomes, although outcomes were numerically worse in patients with NASH. Although the underlying microenvironment and oncogenesis may differ by etiology, further research is needed to identify those most likely to benefit from A/B. [Table: see text]
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Ronac Mamtani
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | | | | | - Yu-Xiao Yang
- Penn Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
8
|
Brown TJ, Massa RC. Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer. JCO Oncol Pract 2022; 18:555-556. [PMID: 35786957 PMCID: PMC9377689 DOI: 10.1200/op.22.00361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 06/09/2022] [Indexed: 08/03/2023] Open
Affiliation(s)
- Timothy J. Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA
| | - Ryan C. Massa
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
9
|
Bange EM, Coughlin K, Li W, Moriarty E, Brown TJ, Shulman LN, Mamtani R. Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors. JAMA Netw Open 2022; 5:e2228452. [PMID: 36036938 PMCID: PMC9425147 DOI: 10.1001/jamanetworkopen.2022.28452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This cross-sectional study examines whether patients with cancer without symptoms of immune checkpoint inhibitor toxic effects can be accurately identified using a text message–based triage instrument and safely proceed to treatment.
Collapse
Affiliation(s)
- Erin M. Bange
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Kerry Coughlin
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Wenrui Li
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia
| | - Elizabeth Moriarty
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Timothy J. Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Lawrence N. Shulman
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Ronac Mamtani
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia
| |
Collapse
|
10
|
Brown TJ, O'Hara MH, Teitelbaum UR, Karasic TB, Schneider CJ, Izgur N, Nathanson KL, Domchek SM, Reiss KA. A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.4131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4131 Background: We recently reported the results of a single arm phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic variant in BRCA1, BRCA2, or PALB2 (NCT 03140670; Reiss, JCO 2021). However, optimal treatment following progression on PARP inhibitors (PARPi) has not been defined. Here, we report a descriptive study of post-progression treatment and outcomes of this patient population. Methods: Patients with advanced pancreatic cancer and germline or somatic BRCA1, BRCA2, or PALB2mutations treated with at least 16 weeks of platinum-based chemotherapy without progression were enrolled and treated with rucaparib until progression or unacceptable toxicity. At the time of progression, patients were treated with physician-choice chemotherapy. Here we evaluate the objective response rates (ORR) by RECIST 1.1. Overall survival (OS) and time to second progression (PFS2) calculated from trial enrollment and progression free survival on chemotherapy (PFS) by regimen were secondary endpoints. Time-to-event was analyzed by the Kaplan-Meier method and censored at date of last clinic visit, with a cutoff date of 12/10/21. Results: The trial enrolled 42 patients; 31 patients had progressed. Of these, 22 received second-line chemotherapy: nine were treated with an oxaliplatin-based regimen, nine were treated with a cisplatin-based regimen, and four were treated with non-platinum regimens. Demographics were balanced between those who received platinum versus non-platinum. All patients who received second-line chemotherapy regimens met the PFS2 endpoint and all but one patient had died at time of data cutoff. No patients had a complete response, five patients had a partial response (PR). By regimen, 1/9 patients treated with cisplatin had a PR, 3/9 treated with oxaliplatin had a PR, and 1/4 patients treated with non-platinum had a PR. OS, PFS2, PFS, and ORR results by regimen are shown in the table. Conclusions: In this small sample of patients with advanced pancreatic cancer with progressive disease on PARPi, chemotherapy retains some activity. Further study to identify predictors of response and/or resistance to post-PARPi treatment are underway. [Table: see text]
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Mark H. O'Hara
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Ursina R. Teitelbaum
- Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | | | | | | | - Katherine L. Nathanson
- Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Susan M. Domchek
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Kim Anna Reiss
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| |
Collapse
|
11
|
Bange EM, Coughlin KQ, Brown TJ, Li W, Moriarty E, Bange TE, Rosin R, Josephs M, Smith DR, Cohen RB, Getz KD, Ragusano D, Balar E, Schuchter LM, Balachandran M, Long Q, Shulman LN, Guerra C, Mamtani R. Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.6527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6527 Background: Patients with cancer spend substantial time receiving cancer care. There is a need for innovative strategies to decrease the time burden of cancer therapy. The current care model consists largely of in-person visits to assess treatment toxicity. Most patients treated with immunotherapy, however, do not experience substantial toxicity. We designed and evaluated a text-based instrument to identify patients without symptoms of immunotherapy toxicity. This instrument has the potential to be combined with lab assessment to identify individuals who can safely proceed directly to treatment, lessening the need for in-person office visits. Methods: This cross-sectional study evaluated the performance characteristics of a text-based instrument to identify patient-reported immunotherapy toxicity, against the gold standard in-person provider assessment documented in the electronic medical record (EMR). Those eligible for inclusion spoke English, were receiving single agent immune checkpoint blockade for a solid tumor, and had access to a mobile device with text messaging capabilities. The instrument contained 16 questions adapted from the NCI Pro-CTCAE and was administered via text-message 96 hours prior to the patient’s scheduled infusion visit. Patient perspectives were quantified via a 13-item questionnaire. Results: Between October 1 and November 25, 2021, 50 patients enrolled in the study, and 45 patients completed the instrument (90% response). The median age was 68 (IQR 60-72), 31 (62%) were male, and 44 (88%) were white. Most patients received either pembrolizumab (n=27, 54%) or nivolumab (n=17, 34%) in the palliative setting (n=37, 74%) for genitourinary (n=15, 30%), lung (n=13, 26%), or skin (n=11, 22%) cancer. Patients who completed the instrument were younger (median age 67 vs 76) than those who did not complete the instrument. The prevalence of immune related toxicity documented in the EMR was 57.8%. The sensitivity and negative predictive value of the instrument was 100% (95% CI 0.87-1.00) and 100% (95% CI 0.664-1.00), respectively; other accuracy parameters are presented in the Table. The patient user questionnaire revealed that visual impairment, lack of access to a smart phone, and lack of recognition of the instrument were barriers to completion. Conclusions: A text-based platform is both feasible and effective at identifying patients who are not experiencing symptoms of immune toxicity, and when combined with lab assessment, can eliminate office visits for up to 47% of patients. A prospective clinical trial to assess this is underway (NCT05134636). [Table: see text]
Collapse
Affiliation(s)
| | | | - Timothy J Brown
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Wenrui Li
- University of Pennsylvania, Philadelphia, PA
| | | | - Tara E. Bange
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | | | | | | | | | - Kelly D. Getz
- The Children's Hospital of Philadelphia, Philadelphia, PA
| | | | - Eesha Balar
- University of Pennsylvania, Philadelphia, PA
| | | | | | - Qi Long
- University of Pennsylvania, Philadelphia, PA
| | | | - Carmen Guerra
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Ronac Mamtani
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
12
|
Brown TJ, Gupta A, Sedhom R, Beg MS, Karasic TB, Yarchoan M. Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. Gastrointest Tumors 2022; 9:19-26. [PMID: 35528745 PMCID: PMC9021659 DOI: 10.1159/000521625] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 12/16/2021] [Indexed: 10/31/2023] Open
Abstract
BACKGROUND Sorafenib has consistently served as the control arm in multiple randomized clinical trials (RCTs) evaluating novel therapies for advanced hepatocellular carcinoma (HCC) for more than a decade. Analyzing trends in clinical outcomes of patients treated with sorafenib for the same indication over time offers the opportunity for unique insight into the evolution of clinical trial conduct and potential non-drug factors impacting outcomes. METHODS We identified RCTs in patients with treatment-naïve advanced HCC where sorafenib was compared to another systemic therapy or placebo. We extracted trial-level demographic, clinicopathologic, and outcome data (overall survival [OS], progression-free survival [PFS], objective response rate [ORR], and duration of therapy). Sample-weighted linear regression was used to identify temporal trends with significance set at p ≤ 0.05. RESULTS Sixteen RCTs (9 phase III and 7 phase II) enrolling 4,086 patients treated with sorafenib were included in the analysis. Included trials enrolled patients from 2005 to 2019. OS has significantly improved by 4.5 months from 2005 to 2019 (p = 0.048) over time. Thirteen studies provided data on PFS using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, with no significant change over time (p = 0.69). ORR assessed by RECIST 1.1 has significantly improved by 6.0% over time (p = 0.003). Median duration of therapy with sorafenib has decreased by 53% since the enrollment of the first clinical trial in 2005, from 23.1 weeks to 12.2 weeks (p = 0.0037). There was no significant change in patient demographics were identified over time to explain the OS findings. CONCLUSION The median OS of patients with advanced HCC treated with sorafenib has improved significantly over 15 years. At the same time, the median duration of therapy with sorafenib has decreased. The reason for these findings was not explained by changing demographics of patients enrolled in these trials and has implications for ongoing clinical trials.
Collapse
Affiliation(s)
- Timothy J. Brown
- Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Arjun Gupta
- Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Ramy Sedhom
- Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Muhammad S. Beg
- Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Thomas B. Karasic
- Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Mark Yarchoan
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
13
|
Karasic TB, Brown TJ, Schneider C, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O’Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O’Dwyer PJ. OUP accepted manuscript. Oncologist 2022; 27:716-e689. [PMID: 35552447 PMCID: PMC9438902 DOI: 10.1093/oncolo/oyac078] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 03/14/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC). Antiangiogenic therapy causes hypoxic stress within tumor cells, which activates autophagy as a survival mechanism. The histone deacetylase inhibitor (HDAC) entinostat increases dependence on autophagy through epigenetic mechanisms. Hydroxychloroquine (HCQ) blocks autophagy by blunting lysosomal acidification. We hypothesized that HCQ and entinostat would be tolerable with regorafenib and potentiate the antitumor response. METHODS This was a 3+3 phase I trial of HCQ and entinostat with regorafenib in patients with metastatic CRC. The primary objective was safety, and the secondary objective was clinical efficacy. RESULTS Twenty patients received study therapy. Six evaluable patients were enrolled at each of the three planned dose levels, one patient at an intermediate dose level, and one additional patient withdrew consent after 4 days to receive treatment closer to home. One dose-limiting toxicity was noted in the study at dose level 2 (grade 3 fatigue). Seven patients discontinued therapy due to related toxicities; rapid weight loss was near universal, with a median weight loss of 4.4 kg (range 1.5-12.2 kg) in the first 2 weeks of treatment. No objective responses were observed. CONCLUSION The combination of regorafenib, HCQ, and entinostat was poorly tolerated without evident activity in metastatic CRC. CLINICALTRIALS.GOV IDENTIFIER NCT03215264.
Collapse
Affiliation(s)
- Thomas B Karasic
- Corresponding author: Thomas B. Karasic, MD, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Tel.: +1 215 615 1594;
| | - Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Charles Schneider
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Kim A Reiss
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Tara C Mitchell
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Ryan C Massa
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Mark H O’Hara
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Lisa DiCicco
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Ravi K Amaravadi
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | | |
Collapse
|
14
|
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, University of Pennsylvania, Philadelphia.,Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Ronac Mamtani
- Abramson Cancer Center, University of Pennsylvania, Philadelphia.,Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| | - Erin M Bange
- Abramson Cancer Center, University of Pennsylvania, Philadelphia.,Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia
| |
Collapse
|
15
|
Abstract
ABSTRACT Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA 19121
| | - Kim A Reiss
- Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA 19121
| |
Collapse
|
16
|
Levonyak NS, Hodges MP, Haaf N, Brown TJ, Hardy S, Mhoon V, Kainthla R, Beg MS, Kazmi SM. Importance of addressing malnutrition in cancer and implementation of a quality improvement project in a gastrointestinal cancer clinic. Nutr Clin Pract 2021; 37:215-223. [PMID: 34339072 DOI: 10.1002/ncp.10753] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Malnutrition is exceedingly common in cancer patients, with some of the highest rates seen in gastrointestinal (GI) malignancies. Malnutrition and cachexia in cancer patients is associated with worse quality of life, poor treatment tolerance, and increased morbidity and mortality. The importance of early recognition of malnutrition in cancer patients is key, and numerous screening tools have been validated to aid practitioners in this diagnosis. In this paper, we summarize the importance of identifying and managing malnutrition in GI cancer patients as well as its impact on clinical outcomes. We then focus on presenting our own novel quality improvement project that aims to expand access to dietitian services in a GI cancer clinic at a large safety-net hospital system. Utilizing evidence-based quality improvement methodologies including the Model for Improvement and Plan-Do-Study-Act cycles, we increased the proportion of GI oncology patients seen by a dietitian from 5% to 20% from October 2018 to July 2019. In particular, we outline the challenges faced in the implementation process of a malnutrition screening tool built into the electronic medical record in an outpatient oncology clinic. We focus on the tool's ability to capture a greater number of patients with malnutrition and its clinical impact.
Collapse
Affiliation(s)
- Nicholas S Levonyak
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Mary P Hodges
- Parkland Health and Hospital System, Dallas, Texas, USA
| | - Nicole Haaf
- Parkland Health and Hospital System, Dallas, Texas, USA
| | - Timothy J Brown
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Shelli Hardy
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.,Harold C. Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Verca Mhoon
- Parkland Health and Hospital System, Dallas, Texas, USA
| | - Radhika Kainthla
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.,Parkland Health and Hospital System, Dallas, Texas, USA
| | - Muhammad Shaalan Beg
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.,Harold C. Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Syed M Kazmi
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.,Parkland Health and Hospital System, Dallas, Texas, USA.,Harold C. Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| |
Collapse
|
17
|
Shah NN, Mathew C, Brown TJ, Karam A, Das SR. A High-Value Care Initiative to Reduce the Use of Intravenous Magnesium Sulfate Through an Electronic Indication-Based Order Set. Jt Comm J Qual Patient Saf 2021; 47:802-808. [PMID: 34364798 DOI: 10.1016/j.jcjq.2021.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 06/14/2021] [Accepted: 06/15/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Intravenous (IV) magnesium sulfate (MgSO4) supplementation is common despite limited indications. Oral magnesium oxide (MgO) is an effective, lower-cost alternative. This project aimed to reduce IV MgSO4 use by 20% among the Internal Medicine (IM) service. METHODS Electronic health record (EHR) orders for MgSO4 and MgO within the IM service were replaced with an indication-based EHR order panel. The project team educated clinicians regarding indications for IV MgSO4 and relative costs. The mean of daily 2 g MgSO4 administrations per week and the mean of weekly proportion of 2 g MgSO4 administrations nine months before and after intervention were compared between IM and Emergency Medicine (EM) (control group). Statistical process control analysis was used to assess for special cause variation in daily MgSO4 per week and weekly proportion of MgSO4 administrations. RESULTS The mean of daily 2 g IV MgSO4 administrations per week decreased among IM (19.3 vs. 12.1, p < 0.0001) but not EM (3.1 vs. 4.8, p < 0.0001). The mean of weekly proportions of IV MgSO4 administrations decreased among both IM (83.6% vs. 60.7%, p < 0.0001) and EM (97.0% vs. 93.1%, p = 0.0004). For IM, the change in daily MgSO4 per week and weekly proportion of MgSO4 occurred as a discrete initial decline consistent with special cause variation; for EM, changes in both measures were not consistent with special cause variation. CONCLUSION Replacing stand-alone IV MgSO4 orders with an indication-based order panel along with clinician education reduced IV MgSO4 administrations and may offer a significant opportunity to reduce low-value care.
Collapse
|
18
|
Brown TJ, Karasic TB, Schneider CJ, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O'Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O'Dwyer PJ. Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e15580] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15580 Background: The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer. Antiangiogenic therapy causes hypoxic stress within tumor cells, which activate autophagy as a survival mechanism. Entinostat, a histone deacetylase (HDAC) inhibitor, increases dependence on autophagy through epigenetic mechanisms. Hydroxychloroquine (HCQ) blocks autophagy by blunting lysosomal acidification and is synergistic with antiangiogenic therapies. We hypothesized that HCQ and entinostat would be tolerable with regorafenib and potentiate the antitumor response. Methods: This was a 3+3 phase I trial to find the recommended phase II dose (RP2D) of HCQ and entinostat with regorafenib in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine, oxaliplatin, and irinotecan. No prior regorafenib or HDAC inhibitor therapy was permitted. Regorafenib was dosed at 160mg daily on days 1-21 of 28-day cycles, with provision to lower the starting dose to 80mg if toxicity was excessive. Entinostat was dosed at 3mg weekly in dose level 1 and at 5mg weekly in dose levels 2 and 3 while HCQ was dosed at 200mg qAM and 400mg qPM in dose levels 1 and 2 and at 600mg BID at dose level 3. Expansion was planned at the RP2D with a primary endpoint of objective response rate. Results: Twenty-eight patients were screened, and 20 patients were enrolled from November 2017 to January 2020. Six patients were treated at dose level 1 with no dose-limiting toxicity. The starting regorafenib dose was reduced to 80mg after 3 patients discontinued therapy early due to fatigue or rash due to regorafenib. At dose level 2, 7 patients were enrolled to achieve 6 evaluable patients. One DLT (G3 fatigue) was noted and one patient withdrew consent after 14 days due to fever and tumor pain flare possibly related to treatment. Six patients enrolled at dose level 3; no DLTs were seen. One additional patient received HCQ 400mg BID instead of 600mg BID due to a clerical error. Weight loss (60%), fatigue (50%), and anorexia (50%) were the most common toxicities. Thirteen grade 3 toxicities were noted, with rash (15%), fatigue (10%), and alkaline phosphatase elevation (10%) the most common. No grade 4 toxicities were observed. Seven patients discontinued therapy early due to toxicity. Nearly all patients experienced rapid weight loss, with a range of 1.5 lbs to 27.1 lbs and a median weight loss of 9.5 lbs at two weeks. No objective responses were observed. The median PFS was 1.8 months, the median OS was 5.2 months, and no patient remained on study longer than 4 months. Expansion was not pursued due to toxicity and lack of efficacy. Conclusions: The combination of regorafenib, HCQ, and entinostat was poorly tolerated without evident activity in metastatic colorectal cancer. The substantial weight loss suggests a potential adverse metabolic interaction between these drugs. Clinical trial information: NCT03215264.
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | | | | | - Ursina R. Teitelbaum
- Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Kim Anna Reiss
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| | - Tara C. Mitchell
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
| | | | - Mark H. O'Hara
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| | - Lisa DiCicco
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| | | | - Ravi K. Amaravadi
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
| | - Peter J. O'Dwyer
- University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
| |
Collapse
|
19
|
Brown TJ, Gupta A, Sedhom R, Karasic TB, Yarchoan M. Trends of clinical outcomes with sorafenib in randomized controlled trials for patients with treatment-naïve advanced hepatocellular carcinoma. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.3_suppl.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
327 Background: Sorafenib was first approved by the US FDA to treat patients with advanced hepatocellular carcinoma (HCC) after two landmark trials (SHARP and Asia-Pacific) showed improved overall survival (OS). Since those two landmark trials, median OS has increased in the sorafenib arms in several recent phase III trials in HCC. We analyzed trends in OS, progression-free survival (PFS), and objective response rates (ORR) in published randomized clinical trials of sorafenib in HCC to better understand factors underlying the improvements. Methods: We searched PubMed for all published trials of sorafenib in advanced HCC. Trials were included if the patients were naïve to systemic therapy and had a comparison arm that was active systemic therapy or placebo. We extracted demographic and trial-level outcome data to correlate outcomes such as OS, PFS, ORR, and duration of therapy. T-tests were used to compare outcomes and linear regression was used to identify temporal trends with significance set at p£0.05. Results: The PubMed search returned 100 studies. A total of 15 studies met inclusion criteria with a total of 3755 patients treated with sorafenib (9 phase III and 6 phase II). Included trials enrolled patients from 2005-2019. The median OS in all trials was 10.0 mos (range: 6.5-14.8 mos). OS has significantly improved since the first trial began accruing (p = 0.04). A total of 12 studies provided data on PFS using RECIST 1.1, with a median PFS of 4.0 months (range: 2.7-6.6 mos). PFS has not changed over time (p = 0.99). However, ORR assessed by RECIST 1.1 have trended toward improvement over time (p = 0.08). Median duration of therapy with sorafenib has decreased by 53% since the enrollment of the first clinical trial in 2005, from 23.1 weeks to 12.2 weeks (p = 0.02). Despite this, no significant correlations were observed with the interaction of duration of therapy and OS (p = 0.92). Further, there was no significant change in the age of patients included, proportion of patients with Childs-Pugh A, Barcelona Clinic Liver Cancer (BCLC) B, BCLC C, ECOG performance status 0, HBV or HCV, proportion of patients with extrahepatic spread or vascular invasion at time of enrollment, or proportion of patients who have undergone prior locoregional therapies to explain the OS findings. Conclusions: The OS of patients with advanced HCC on the sorafenib arm in published trials has been increasing, however the reasons for this increase are not apparent from data available in the published literature. At the same time, the median duration of treatment with sorafenib has been decreasing over time and PFS is unchanged, suggesting improvements in sorafenib delivery may not be the primary factor. It is possible these trends represent heretofore unquantified changes in patient selection for systemic therapy, improvements in supportive care, or post-progression treatment for patients on HCC clinical trials.
Collapse
Affiliation(s)
- Timothy J Brown
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Ramy Sedhom
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | | | - Mark Yarchoan
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
20
|
Williams E, Brown TJ, Griffith P, Rahimi A, Oilepo R, Hammers H, Laetsch TW, Currykosky P, Partridge S, Beg MS. Improving the Time to Activation of New Clinical Trials at a National Cancer Institute–Designated Comprehensive Cancer Center. JCO Oncol Pract 2020; 16:e324-e332. [DOI: 10.1200/op.19.00325] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE: The time it takes a performing site to activate a clinical trial can directly affect the ability to provide innovative and state-of-the-art care to patients. We sought to understand the process of activating an oncology clinical trial at a matrix National Cancer Institute–designated comprehensive cancer center. METHODS: A multidisciplinary team of stakeholders within the cancer center, university, and affiliate hospitals held a retreat to map out the process of activating a clinical trial. We applied classical quality improvement and Six Sigma methodology to determine bottlenecks and non–value-added time in activating a clinical trial. During this process, attention was paid to time to pass through each step, and perceived barriers and bottlenecks were identified through group discussions. RESULTS: The process map identified 66 steps with 12 decision points to activate a new clinical trial. The following two steps were instituted first: allow parallel scientific committee and institutional review board (IRB) review and allow the clinical research coordination committee, a group that determines university interest and feasibility, to review protocols independent of the IRB and scientific committee approval. The clinical research coordination committee continues to track the activation time, and this framework is used to identify additional improvement steps. CONCLUSION: By applying quality improvement methodologies and Six Sigma principles, we were able to identify redundancies in the process to activate a clinical trial. This allowed us to redesign the process of activating a clinical trial at a matrix comprehensive cancer center. More importantly, the process map provides a framework to maintain these gains and implement additional changes and serves as an example to deploy across the campus and at other similar institutions.
Collapse
Affiliation(s)
- Erin Williams
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | - Asal Rahimi
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Rhonda Oilepo
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Hans Hammers
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Theodore W. Laetsch
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
- Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX
- Children’s Health, Dallas, TX
| | - Penny Currykosky
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
| | | | - Muhammad S. Beg
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
- The University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|
21
|
|
22
|
Abstract
Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled pain, superinfection or systemic infection, bleeding, and dehydration, and severe mucositis can lead to interruptions or de-escalation in anticancer treatment, resulting in worse oncologic outcomes. This article provides an evidence-based summary to guide practicing oncologists in the assessment, prevention, and management of mucositis induced by chemotherapy, radiotherapy, and targeted therapy.
Collapse
Affiliation(s)
- Timothy J Brown
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX
| | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
| |
Collapse
|
23
|
|
24
|
Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials. Am J Clin Oncol 2019; 42:270-274. [PMID: 30628912 DOI: 10.1097/coc.0000000000000514] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
INTRODUCTION Neutropenic diets are commonly prescribed to cancer patients with neutropenia with the intention of reducing rates of infection. These diets are restrictive and are associated with lower patient satisfaction and possibly malnutrition. Further, it is unclear if these restrictive diets are effective in reducing infection. We performed a meta-analysis on the rates of infection reported in trials comparing the neutropenic diet to unrestricted diets in cancer patients with neutropenia. METHODS AND MATERIALS A comprehensive database search for all published randomized controlled trials comparing infection rates in cancer patients receiving a neutropenic diet versus an unrestricted diet was performed for all publications in English language from database's inception until September 12, 2017. The search strategy, study selection, and subsequent analysis adhered to PRISMA guidelines. Random effects modeling was used to obtain pooled relative risks. The primary outcome measure was the rate of infection. RESULTS Five randomized controlled trials with a total of 388 patients were included in the final analysis. Patients mostly had acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or sarcoma. Infection was noted in 53.7% patients in the neutropenic diet group, as compared with 50% in the unrestricted diet group. No significant difference in infection rate was observed between the neutropenic diet versus unrestricted diet groups, pooled risk ratio (RR) 1.13 (95% CI, 0.98-1.30; P=0.10). CONCLUSIONS This meta-analysis of randomized controlled trials suggests that the use of neutropenic diet was not associated with decreased risk of infection in neutropenic cancer patients. The continued use of neutropenic diets should be questioned.
Collapse
Affiliation(s)
- Somedeb Ball
- Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock
| | | | - Avash Das
- Department of Cardiology, Massachusetts General Hospital, Boston, MA
| | - Rohan Khera
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
| | - Sahil Khanna
- Division of Gastroenterology, Mayo Clinic, Rochester, MN
| | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD
| |
Collapse
|
25
|
Brown TJ, Patel PA, Oliver D, Churchill H, Monaghan SA, Collins RH. Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia. JCO Precis Oncol 2019; 3:1-6. [DOI: 10.1200/po.18.00291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Prapti A. Patel
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Dwight Oliver
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Hywyn Churchill
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | |
Collapse
|
26
|
Abstract
Background Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder resulting from dysregulated cytokine production. The diagnosis of HLH requires five of eight abnormalities: fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, hyperferritinemia, hemophagocytosis on biopsy, low or absent NK cell activity, or elevated soluble CD25. The link between Human Immunodeficiency Virus (HIV) and HLH is incompletely understood; we sought to further define the characteristics and outcomes of this patient population. Methods We performed a retrospective study on HLH patients with and without concurrent HIV infection treated at our institution from January 2008 to July 2018. At the time of HLH diagnosis, we extracted data on the HIV status and associated malignancies. The primary outcome was overall survival from time of diagnosis of HLH in patients with HIV vs. those without HIV. Secondary analysis was performed with survival by HIV and malignancy status. Survival was analyzed by Kaplan–Meier curves with hazard ratios calculated using the log-rank test with significance set at P ≤ 0.05. Results Forty-three patients were included; 11 had HIV at the time of diagnosis of HLH and all met criteria for AIDS at time of inclusion. Patients with HIV who were diagnosed with HLH had similar survival compared with patients without HIV (Hazard ratio for death (HR) 0.87 [95% confidence interval (CI) 0.37–2.904]). All patients with malignancy had a worse survival (HR for death 3.648 [95% CI 1.804–9.169] P = 0.0009), regardless of HIV status. HLH in HIV patients with malignancy resulted in a trend toward worse survival (HR = 3.86 95% CI 1.09–22.60, P = 0.0578) compared with those without malignancy, although the limited number of patients prohibits a definitive conclusion. In HIV-negative patients, the presence of malignancy is associated with worse survival (HR 3.56 [95% CI 1.475–10.11] P = 0.0063). Conclusion In this retrospective, single-institution review of HLH patients, HIV was not associated with worse overall survival compared with patients without HIV. The presence of malignancy resulted in worse survival in the overall population. Further investigation is needed to optimize the care of these patients. ![]()
Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Timothy J Brown
- University of Texas Southwestern Medical Center, Dallas, Texas
| | | | | | | |
Collapse
|
27
|
Brown TJ, Williams EF, Griffith P, Rahimi AS, Oilepo R, Hammers HJ, Laetsch TW, Kurian P, Currykosky P, Partridge S, Beg MS. Applying quality improvement methodologies to decrease the time-to-activation of new clinical trials at an NCI-designated comprehensive cancer center. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.27_suppl.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
296 Background: Initiating a new clinical trial is burdensome and complex. The time to activate a clinical trial can directly affect the ability to provide innovative, state-of-the-art care to patients. We sought to understand the process of activating an oncology clinical trial at a matrix National Cancer Institute-designated, comprehensive cancer center. Methods: A multidisciplinary team of stakeholders within the cancer center, university, and affiliate hospitals held a retreat to map out the process of activating a clinical trial from packet receipt to enrollment of the first patient. We applied classical QI and Six Sigma methodology to determine bottlenecks and redundancies in activating a clinical trial. During this process, particular attention was paid to time to pass through each step and perceived barriers and bottlenecks were identified through group discussions. The time to activation was measured from the day the trial packet was received until the time when the trial was open for enrollment. Results: The process map identified 66 steps with 12 decision points to activate a new clinical trial. The following two steps were instituted first: 1) allow parallel scientific committee and institutional review board (IRB) review and 2) allow the clinical research coordination committee to review protocols for feasibility and university interest separate from the IRB approval process. These changes resulted in a mean time-to-activation change from 194 days at baseline to 135 days after these changes were implemented. The committee continues to track the activation time and this frame work is used to identify additional improvement steps. Conclusions: By applying quality improvement methodologies and Six Sigma principles, we were able to redesign redundant aspects of the process of activating a clinical trial at a matrix comprehensive cancer center. This was associated with a reduction of time to activation of trials. More importantly, the process map provides a framework to maintain these gains and implement further changes.
Collapse
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Erin Fenske Williams
- Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
| | | | - Asal Shoushtari Rahimi
- Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
| | - Rhonda Oilepo
- University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | - Pamela Kurian
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | | |
Collapse
|
28
|
Keshvani N, Hon M, Gupta A, Brown TJ, Roy L, Marley E, Lindsey S, Johnson DH, Sadeghi N, Li HC. Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital. J Oncol Pract 2019; 15:e644-e651. [DOI: 10.1200/jop.18.00738] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE: EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) -based chemotherapy is traditionally administered inpatient because of its complex 96-hour protocol and number of involved medications. These routine admissions are costly, disruptive, and isolating to patients. Here, we describe our experience transitioning from inpatient to outpatient ambulatory EPOCH-based chemotherapy in a safety-net hospital, associated cost savings, and patient perceptions. METHODS AND MATERIALS: Guidelines for chemotherapy administration and educational materials were developed by a multidisciplinary team of physicians, nurses, and pharmacists. Data were collected via chart review and costs via the finance department. Patient satisfaction with chemotherapy at home compared with hospitalization was measured on a Likert-type scale via direct-to-patient survey. RESULTS: From January 30, 2017, through January 30, 2018, 87 cycles of EPOCH-based chemotherapy were administered to 23 patients. Sixty-one ambulatory cycles (70%) were administered to 18 patients. Of 26 cycles administered in the hospital, 18 (69%) were the first cycle of treatment. Rates of inappropriate prophylactic antimicrobial prescription and laboratory testing were lower in the outpatient setting. Eight of nine patients surveyed preferred home chemotherapy to inpatient chemotherapy. Per-cycle drug costs were 57.6% lower in outpatients as a result of differences in the acquisition cost in the outpatient setting. In total, the transition to ambulatory EPOCH-based chemotherapy yielded 1-year savings of $502,030 and an estimated 336 days of avoided hospital confinement. CONCLUSION: Multiday ambulatory EPOCH-based regimens were successfully and safely administered in our safety-net hospital. Outpatient therapy was associated with significant savings through avoided hospitalizations and reductions in drug acquisition cost and improved patient satisfaction.
Collapse
Affiliation(s)
- Neil Keshvani
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Mary Hon
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Arjun Gupta
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Timothy J. Brown
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Lonnie Roy
- Parkland Health and Hospital System, Dallas, TX
| | | | | | - David H. Johnson
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Navid Sadeghi
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| | - Hsiao C. Li
- University of Texas Southwestern Medical Center, Dallas, TX
- Parkland Health and Hospital System, Dallas, TX
| |
Collapse
|
29
|
Affiliation(s)
- Bruno Alvarez Concejo
- Resident, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; ; ORCID: https://orcid.org/0000-0002-2695-8159. Resident, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; ORCID: https://orcid.org/0000-0003-4205-3787. Chief resident, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; ORCID: https://orcid.org/0000-0002-4843-4639
| | | | | |
Collapse
|
30
|
Brown TJ, Mukhija D, Premnath N, Venkatraman A, Jiv Singh Nagpal S, Gupta A. Dissemination of Information on Neutropenic Diet by Top US Cancer Centers: In-line with the Evidence? Nutr Cancer 2019; 71:1272-1275. [DOI: 10.1080/01635581.2019.1606262] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Timothy J. Brown
- Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | | | - Naveen Premnath
- Department of Medicine, Mount Sinai St Luke Roosevelt Medical Center, New York, New York, USA
| | - Anand Venkatraman
- Department of Neurology, Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
| | | | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
31
|
Pokala N, Singh S, Hu G, Brown TJ, Pandey A, Das SR, Gupta A. Promoting High-Value Change by Addressing the Structure of Order Sets: Lessons From the Cardiac Catheterization Lab. Am J Med Qual 2019; 34:312. [DOI: 10.1177/1062860618798920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | - Shruti Singh
- The University of Texas Southwestern Medical Center
| | - Gene Hu
- The University of Texas Southwestern Medical Center
| | | | | | | | - Arjun Gupta
- The University of Texas Southwestern Medical Center
| |
Collapse
|
32
|
Affiliation(s)
- Angad S Uberoi
- Department of Internal Medicine, Mount Sinai St Luke's and Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Timothy J Brown
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
| | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
| |
Collapse
|
33
|
Abstract
A 61-year-old Hispanic man presented to a county hospital for subacute progressive weakness, heliotrope rash and dysphagia. There was initial suspicion for dermatomyositis (DM) given the history; however, the physical exam was not consistent. An MRI followed by a muscle biopsy revealed necrotising autoimmune myositis and anti-3-hydroxy-3-methylglutary-coenzyme A-reductase antibody titers returned positive; the patient was diagnosed with necrotising autoimmune myositis. He was treated with corticosteroids and intravenous immunoglobulin, which resulted in improvement in his weakness and functional status. This case represents a unique instance in which a cardinal feature of DM, the heliotrope rash, prompted an erroneous initial diagnosis. It highlights the necessity of developing abroad differential diagnosis and subsequent thorough investigation into patients presenting with suspected idiopathic immune-mediated myopathies.
Collapse
Affiliation(s)
- Gary Parizher
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Timothy J Brown
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Mary Hon
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Elena K Joerns
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Yu Zuo
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| |
Collapse
|
34
|
Shah NN, Mathew C, Brown TJ, Agrawal D, Das SR. Abstract 12: Overutilization and Financial Impact of Intravenous Magnesium Repletion - a High Value Care Initiative. Circ Cardiovasc Qual Outcomes 2019. [DOI: 10.1161/hcq.12.suppl_1.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Serum magnesium levels ([Mg]) are often maintained at >2 mg/dl in hospital patients, especially those on cardiology services, despite a poor correlation between serum and total body Mg stores and lack of data supporting routine Mg repletion. Oral Mg oxide (MgO) is as effective as intravenous (IV) Mg sulfate (MgSO
4
) at repleting Mg stores but is significantly more expensive.
Objective:
To determine the frequency and relative cost impact of IV versus oral Mg repletion.
Methods:
We queried our EHR for all instances in which Mg was administered within 24 hours after a serum [Mg] measurement among adults at a large, tertiary-care county hospital from 10/2016 to 10/2018, excluding obstetric and perioperative uses. The data collected included serum [Mg], route of administration, and patient location. Using the hospital medication cost for IV and oral Mg, we determined the potential cost savings of a change in route (medication costs only, not including administration costs). This quality improvement study was deemed exempt from IRB review.
Results:
Overall, there were 46,852 instances of Mg repletion. The IV route was used in 80% cases, of which 53% were for serum Mg ≥ 1.8 mg/dL. The mean serum [Mg] preceding repletion was 1.80 and 1.84 mg/dL for the IV and oral routes, respectively (p<0.0001). The estimated direct cost savings of repleting Mg after a serum [Mg] of ≥ 1.8 mg/dL with 400mg oral MgO instead of 2g IV MgSO
4
was $193,210 over 2 years.
Conclusion:
IV Mg repletion for mild hypomagnesemia was common. The mean serum [Mg] for patients treated by the IV versus oral routes were not meaningfully different, suggesting route differences are not driven by perceived severity of hypomagnesemia. Overall, the pattern of IV MgSO
4
use at our institution suggests widespread overuse with a substantial financial impact. We expect this pattern of use may be present at other institutions, and that cardiologists can play a lead role in reducing unnecessary testing. Further implementation studies of strategies to reduce IV use are warranted.
Collapse
|
35
|
Patel KK, Brown TJ, Gupta A, Roberts T, Marley E, Li HC, Sadeghi N. Decreasing Inappropriate Use of Rasburicase to Promote Cost-Effective Care. J Oncol Pract 2019; 15:e178-e186. [PMID: 30673367 DOI: 10.1200/jop.18.00528] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Rasburicase is a recommended treatment of tumor lysis syndrome and patients at high-risk for developing tumor lysis syndrome. Unfortunately, it is expensive, and unnecessary use raises costs of care. METHODS Plan, Do, Study, Act methodology was used to decrease the inappropriate use of rasburicase. In the Plan phase, a multidisciplinary quality improvement team reviewed the rasburicase ordering process and its prescription patterns at Parkland Health and Hospital System between October 2015 and September 2017 to determine appropriate interventions for improvement. In the Do phase, interventions were deployed to improve rasburicase prescriptions. In the Study phase, the team reviewed the rasburicase orders and appropriateness from February 2018 to October 2018. During the Act phase, the interventions were found to be successful, and the process changes were solidified. RESULTS At baseline, 65 doses of rasburicase were administered during the 2-year baseline period, 21 of these (32.3%) were inappropriate. Review of the ordering process identified pitfalls: one-click ready-to-sign order, fixed default dose, no hard-stop alert requiring physicians to review and confirm appropriate indications, and lack of secondary pharmacy review. We aimed to reduce the percentage of inappropriate rasburicase orders from a baseline of 32.3% to 10% over 3 months. In February 2018, we implemented the interventions, which resulted in reduction in inappropriate rasburicase use, with only a single inappropriate order placed in 7 months postintervention. CONCLUSION A multidisciplinary approach and classic quality improvement methodology enabled us to reduce inappropriate rasburicase use. Straightforward electronic medical record interventions and secondary pharmacy review are effective in addressing overuse.
Collapse
Affiliation(s)
- Komal K Patel
- 1 University of Texas Southwestern Medical Center, Dallas, TX
| | - Timothy J Brown
- 1 University of Texas Southwestern Medical Center, Dallas, TX
| | - Arjun Gupta
- 2 Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Taylor Roberts
- 1 University of Texas Southwestern Medical Center, Dallas, TX
| | | | - Hsiao C Li
- 1 University of Texas Southwestern Medical Center, Dallas, TX
| | - Navid Sadeghi
- 1 University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|
36
|
Abstract
Sphingolipids represent one of the major classes of bioactive lipids. Studies of sphingolipids have intensified in the past several years, revealing their roles in nearly all cell biological processes. In addition, epigenetic regulation has gained substantial interest due to its role in controlling gene expression and activity without changing the genetic code. In this review, we first introduce a brief background on sphingolipid biology, highlighting its role in pathophysiology. We then illustrate the concept of epigenetic regulation, focusing on how it affects the metabolism of sphingolipids. We further discuss the roles of bioactive sphingolipids as epigenetic regulators themselves. Overall, a better understanding of the relationship between epigenetics and sphingolipid metabolism may help to improve the development of sphingolipid-targeted therapeutics.
Collapse
Affiliation(s)
- Weiyuan Wang
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| | - Paul T Toran
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| | - Rachel Sabol
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| | - Timothy J Brown
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390 USA
| | - Brian M Barth
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| |
Collapse
|
37
|
Affiliation(s)
- Angad S Uberoi
- Department of Internal Medicine, Mount Sinai St Luke's and Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Timothy J Brown
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
| | - Arjun Gupta
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
| |
Collapse
|
38
|
Sumarsono A, Brown TJ, Atkin SD, Clark J. A 57-Year-Old Man With Subacute Progressive Hemoptysis and Fevers. Chest 2018; 154:e181-e185. [PMID: 30526987 DOI: 10.1016/j.chest.2018.07.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Revised: 06/25/2018] [Accepted: 07/24/2018] [Indexed: 10/27/2022] Open
Abstract
CASE PRESENTATION A 57-year-old man was admitted for 1 month of accelerating hemoptysis and hematemesis. Two weeks earlier, he first presented with fevers and hemoptysis of 2 weeks' duration and was diagnosed with community-acquired pneumonia treated with 5 days of ceftriaxone and azithromycin. He improved and was discharged, but his hemoptysis recurred 1 day after discharge and progressed over 9 days, leading to the present admission. He endorsed an 5-kg weight loss, daily fevers up to 39.4°C, and night sweats since discharge. His medical history was significant for peptic ulcer disease complicated by a perforated gastric ulcer 30 years ago, type 2 diabetes, and Barrett esophagus with recent normal upper endoscopy. The patient had coarctation of the aorta repaired 35 years ago. The patient takes aspirin, atorvastatin, and pantoprazole. He emigrated from Mexico 10 years before presentation and lives in Texas with his family. He returns to Mexico several times per year, most recently 2 days before admission. He works at a supermarket. He does not smoke, drink, or use illicit drugs. He denied sick contacts, pets, or incarceration.
Collapse
Affiliation(s)
- Andrew Sumarsono
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX
| | - Timothy J Brown
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX
| | - Stan D Atkin
- Department of Medicine, Oregon Health Sciences University, Portland, OR
| | - Jason Clark
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.
| |
Collapse
|
39
|
Brown TJ, Wolfe HR, Hardy S, Bhulani N, Hong C, Khosama L, Cheedella N, Hobbs S, Froehlich TW, Kamal A, Beg MS, Kazmi SMA. Development of a nutrition-focused quality improvement program for new patients with cancer seen at the UTSW Simmons Comprehensive Cancer Center (SCCC) outpatient gastrointestinal (GI) oncology clinic. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.30_suppl.143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
143 Background: Patients with GI malignancies suffer from weight loss, sarcopenia and malnutrition contributing to poor outcomes and reduced survival. Early nutritional intervention in at-risk patients by a clinical dietitian can prevent or delay the onset of malnutrition. In the GI Oncology clinic at the UTSW SCCC, the rate of documented nutritional plan by a clinical dietitian within first 90 days of new patient encounter was low. Methods: We aimed to increase the rate of a documented nutrition assessment by a clinical dietitian to 65% within 90 days of a new patient encounter. Baseline data from the electronic medical record were obtained from Sep 2017-Oct 2018. Group sessions were arranged to apply QI methodologies to determine steps to a documented nutritional plan by a clinical dietitian. Patient advocates were interviewed to assess patient perspective. Sequential PDSA cycles were planned to improve rates of nutritional plan documentation and data were obtained every 2 weeks. Results: At baseline, 41.1% of new patients in the two-month data collection period had documented nutrition plans within 90 days of their first appointment. Most of these patients were on intravenous chemotherapy. EMR-based nutrition assessments identified 17% of all new patients at risk of malnutrition. Multiple causes for low baseline rates of nutrition plans were discovered, including patient or family characteristics and needs, clinical dietitian resources, physician limitations, process flaws, as well as difficulty with the EMR. Patient-centered PDSA cycles directed toward patients, and clinical staff to increase the rate of documented nutritional plan are ongoing. After the first PDSA cycle, early 2-week assessment shows documented rate of nutritional plan of 28%. Authors expect it to increase with longer follow-up and subsequent PDSA cycles. Conclusions: Malnutrition in GI cancer is prevalent and under-recognized in routine clinical encounters. Addressing malnutrition is important aspect from patient perspective. We are continuing ongoing efforts to increase the rate of nutritional assessments in these patients.
Collapse
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Heather R Wolfe
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Shelli Hardy
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Nizar Bhulani
- University of Texas Southwestern Medical Center, Dallas, TX
| | - Christine Hong
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | - Naga Cheedella
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Stephanie Hobbs
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | | | | |
Collapse
|
40
|
Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract 2018; 6:249-258. [PMID: 31386075 DOI: 10.1093/nop/npy034] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma. Methods A quantitative systematic review was performed. Inclusion criteria included controlled trials of newly diagnosed low-grade (World Health Organization Grades I and II) gliomas in adults. Eligible studies were identified, assigned a level of evidence for every endpoint considered, and analyzed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The relative risk of mortality and of progression at 2, 5, and 10 years was calculated for patients undergoing resection (gross total, subtotal, or biopsy), radiation, or chemotherapy. Results Gross total resection was significantly associated with decreased mortality and likelihood of progression at all time points compared to subtotal resection. Early radiation was not associated with decreased mortality; however, progression-free survival was better at 5 years compared to patients receiving delayed or no radiation. Chemotherapy was associated with decreased mortality at 5 and 10 years in the high-quality literature. Progression-free survival was better at 5 and 10 years compared to patients who did not receive chemotherapy. In patients with isocitrate dehydrogenase 1 gene (IDH1) R132H mutations receiving chemotherapy, progression-free survival was better at 2 and 5 years than in patients with IDH1 wild-type gliomas. Conclusions Results from this review, the first to quantify differences in outcome associated with surgery, radiation, and chemotherapy in patients with low-grade gliomas, can be used to inform evidence-based management and future clinical trials.
Collapse
Affiliation(s)
- Timothy J Brown
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas
| | - Daniela A Bota
- Department of Neurology, University of California Irvine, USA.,Department of Neurological Surgery, University of California Irvine, USA
| | | | - Paul D Brown
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Elizabeth Maher
- Department of Medicine, The University of Texas Southwestern Medical Center, Dallas
| | - Dawit Aregawi
- Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.,Department of Oncology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
| | - Linda M Liau
- Department of Neurological Surgery, University of California Los Angeles, USA
| | | | - Michael Weller
- Department of Neurology, University Hospital and University of Zurich, Switzerland
| | - Mitchel S Berger
- Department of Neurological Surgery, University of California San Francisco, USA
| | - Michael Glantz
- Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.,Department of Oncology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
| |
Collapse
|
41
|
McGill CM, Tomco PL, Ondrasik RM, Belknap KC, Dwyer GK, Quinlan DJ, Kircher TA, Andam CP, Brown TJ, Claxton DF, Barth BM. Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia. Phytother Res 2018; 32:1636-1641. [PMID: 29701283 PMCID: PMC7992109 DOI: 10.1002/ptr.6091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 03/14/2018] [Accepted: 03/16/2018] [Indexed: 12/20/2022]
Abstract
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is one of the more common pediatric malignancies in addition to occurring with high incidence in the aging population. Unfortunately, these patient groups are quite sensitive to toxicity from chemotherapy. Northern Labrador tea, or Rhododendron tomentosum Harmaja (a.k.a. Ledum palustre subsp. decumbens) or "tundra tea," is a noteworthy medicinal plant used by indigenous peoples in Alaska, Canada, and Greenland to treat a diversity of ailments. However, laboratory investigations of Northern Labrador tea, and other Labrador tea family members, as botanical sources for anticancer compounds have been limited. Utilizing an AML cell line in both in vitro and in vivo studies, as well as in vitro studies using primary human AML patient samples, this study demonstrated for the first time that Northern Labrador tea extracts can exert anti-AML activity and that this may be attributed to ursolic acid as a constituent component. Therefore, this medicinal herb holds the potential to serve as a source for further drug discovery efforts to isolate novel anti-AML compounds.
Collapse
Affiliation(s)
- Colin M. McGill
- Department of Chemistry, University of Alaska Anchorage,
Anchorage, AK 99508 USA
| | - Patrick L. Tomco
- Department of Chemistry, University of Alaska Anchorage,
Anchorage, AK 99508 USA
| | - Regina M. Ondrasik
- Department of Medicine, Division of Hematology and
Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine,
Hershey, PA 17033 USA
| | - Kaitlyn C. Belknap
- Department of Molecular, Cellular and Biomedical Sciences,
University of New Hampshire, Durham, NH 03824 USA
| | - Gaelen K. Dwyer
- Department of Chemistry, University of Alaska Anchorage,
Anchorage, AK 99508 USA
| | - Daniel J. Quinlan
- Department of Chemistry, University of Alaska Anchorage,
Anchorage, AK 99508 USA
| | - Thomas A. Kircher
- Department of Chemistry, University of Alaska Anchorage,
Anchorage, AK 99508 USA
| | - Cheryl P. Andam
- Department of Molecular, Cellular and Biomedical Sciences,
University of New Hampshire, Durham, NH 03824 USA
| | - Timothy J. Brown
- Department of Medicine, Division of Hematology and
Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine,
Hershey, PA 17033 USA
| | - David F. Claxton
- Department of Medicine, Division of Hematology and
Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine,
Hershey, PA 17033 USA
| | - Brian M. Barth
- Department of Medicine, Division of Hematology and
Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine,
Hershey, PA 17033 USA
- Department of Molecular, Cellular and Biomedical Sciences,
University of New Hampshire, Durham, NH 03824 USA
| |
Collapse
|
42
|
Brown TJ, Zoccoli CM, Ali A, Kim LJ, Glantz MJ. Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | - Ayesha Ali
- Penn State Hershey Medical Center, Hershey, PA
| | | | | |
Collapse
|
43
|
Brown TJ, Tawfik B. Effectiveness of biomarker surveillance after treatment in locoregional breast cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e12608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Bernard Tawfik
- University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|
44
|
Bishop TM, Ashrafioun L, Walsh PG, Klein JS, Brown TJ, Pigeon WR. 0952 Sleep, Suicide Risk, and the Protective Role Of Sleep Medicine. Sleep 2018. [DOI: 10.1093/sleep/zsy061.951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T M Bishop
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| | - L Ashrafioun
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| | - P G Walsh
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| | - J S Klein
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| | - T J Brown
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| | - W R Pigeon
- VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
| |
Collapse
|
45
|
Hendren NS, Panach K, Brown TJ, Peng L, Beg MS, Weissler J, Mirfakhraee S. Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. Clin Endocrinol (Oxf) 2018; 88:341-343. [PMID: 29055143 DOI: 10.1111/cen.13503] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Nicholas S Hendren
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Kamaldeep Panach
- Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Timothy J Brown
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Lan Peng
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Muhammad S Beg
- Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Jonathan Weissler
- Division of Pulmonology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Sasan Mirfakhraee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| |
Collapse
|
46
|
McGill CM, Brown TJ, Fisher LN, Gustafson SJ, Dunlap KL, Beck AJ, Toran PT, Claxton DF, Barth BM. Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia. Int J Biopharm Sci 2018; 1:106. [PMID: 30701264 PMCID: PMC6349237 DOI: 10.31021/ijbs.20181106] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with limited treatment options. Inflammation is often a contributing factor to the development and progression of AML, and related diseases, and can potentiate therapy failure. Previously, we had identified anti-inflammatory roles and anti-AML efficacy for blueberry extracts. The present study extended these observations to determine that the polyphenol quercetin inhibited neutral sphingomyelinase (N-SMase) activity and exerted anti-AML efficacy. Moreover, quercetin was shown to exert combinatorial anti-AML efficacy with nanoliposomal ceramide. Overall, this demonstrated that quercetin could block the pro-inflammatory actions of N-SMase and augment the efficacy of anti-AML therapeutics, including ceramide-based therapeutics.
Collapse
Affiliation(s)
- Colin M McGill
- Department of Chemistry, University of Alaska-Anchorage, Anchorage, AK 99508 USA
| | - Timothy J Brown
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
- Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390 USA
| | - Lindsey N Fisher
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Sally J Gustafson
- Department of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775
| | - Kriya L Dunlap
- Department of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775
| | - Adam J Beck
- Drug Discovery, Development, and Delivery Core, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Paul T Toran
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| | - David F Claxton
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Brian M Barth
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| |
Collapse
|
47
|
McGill CM, Brown TJ, Cheng YY, Fisher LN, Shanmugavelandy SS, Gustafson SJ, Dunlap KL, Lila MA, Kester M, Toran PT, Claxton DF, Barth BM. Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia. Int J Biopharm Sci 2018; 1:102. [PMID: 29607443 PMCID: PMC5875929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with high incidence in the aging population. In addition, AML is one of the more common pediatric malignancies. Unfortunately, both of these patient groups are quite sensitive to chemotherapy toxicities. Investigation of blueberries specifically as an anti-AML agent has been limited, despite being a prominent natural product with no reported toxicity. In this study, blueberry extracts are reported for the first time to exert a dietary therapeutic effect in animal models of AML. Furthermore, in vitro studies revealed that blueberry extracts exerted anti-AML efficacy against myeloid leukemia cell lines as well as against primary AML, and specifically provoked Erk and Akt regulation within the leukemia stem cell subpopulation. This study provides evidence that blueberries may be unique sources for anti-AML biopharmaceutical compound discovery, further warranting fractionation of this natural product. More so, blueberries themselves may provide an intriguing dietary option to enhance the anti-AML efficacy of traditional therapy for subsets of patients that otherwise may not tolerate rigorous combinations of therapeutics.
Collapse
Affiliation(s)
- Colin M. McGill
- Department of Chemistry, University of Alaska-Anchorage, Anchorage, AK 99508 USA
| | - Timothy J. Brown
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Yuan-Yin Cheng
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Lindsey N. Fisher
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | | | - Sally J. Gustafson
- Department of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775 USA
- Plants for Human Health Institute, North Carolina State University, North Carolina Research Campus, Kannapolis, NC 28081 USA
| | - Kriya L. Dunlap
- Department of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775 USA
| | - Mary Ann Lila
- Plants for Human Health Institute, North Carolina State University, North Carolina Research Campus, Kannapolis, NC 28081 USA
| | - Mark Kester
- Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033 USA
- Department of Pharmacology, University of Virginia, Charlottesville, VA 22908 USA
| | - Paul T. Toran
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| | - David F. Claxton
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
| | - Brian M. Barth
- Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA
- Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033 USA
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA
| |
Collapse
|
48
|
Brown TJ, O'Malley C, Blackshaw J, Coulton V, Tedstone A, Summerbell C, Ells LJ. Exploring the evidence base for Tier 3 weight management interventions for adults: a systematic review. Clin Obes 2017; 7:260-272. [PMID: 28695579 DOI: 10.1111/cob.12204] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 05/15/2017] [Accepted: 06/05/2017] [Indexed: 11/30/2022]
Abstract
Specialist weight management services provide a treatment option for severe obesity. The objective of the study is to review the characteristics, impact and practice implications of specialist weight management services for adults in the UK. Systematic review: EMBASE, MEDLINE and PsycINFO were searched from January 2005 to March 2016 with supplementary searches. Adults with a body mass index of ≥40 kg m-2 , or ≥35 kg m-2 with comorbidity or ≥30 kg m-2 with type 2 diabetes and any study of multicomponent interventions, in any UK or Ireland setting, delivered by a specialist multidisciplinary team are the inclusion criteria. Fourteen studies in a variety of settings were included: 1 randomized controlled trial, 3 controlled and 10 observational studies. Mean baseline body mass index and age ranged from 40 to 54 kg m-2 and from 40 to 58 years. The studies were heterogeneous making comparisons of service characteristics difficult. Multidisciplinary team composition and eligibility criteria varied; dropout rates were high (43-62%). Statistically significant reduction in mean body mass index over time ranged from -1.4 to -3.1 kg m-2 and mean weight changes ranged from -2.2 to -12.4 kg. Completers achieving at least 5% reduction of initial body weight ranged from 32 to 51%. There was evidence for improved outcomes in diabetics. Specialist weight management services can demonstrate clinically significant weight loss and have an important role in supporting adults to manage severe and often complex forms of obesity. This review highlights important variations in provision and strongly indicates the need for further research into effective approaches to support severely obese adults.
Collapse
Affiliation(s)
- T J Brown
- School of Health and Social Care, Teesside University, Middlesbrough, UK
- FUSE, Centre for Translational Research in Public Health, North East England, UK
| | - C O'Malley
- School of Health and Social Care, Teesside University, Middlesbrough, UK
- FUSE, Centre for Translational Research in Public Health, North East England, UK
| | - J Blackshaw
- Diet and Obesity; Health and Wellbeing, Public Health England, London, UK
| | - V Coulton
- Diet and Obesity; Health and Wellbeing, Public Health England, London, UK
| | - A Tedstone
- Diet and Obesity; Health and Wellbeing, Public Health England, London, UK
| | - C Summerbell
- FUSE, Centre for Translational Research in Public Health, North East England, UK
- School of Applied Social Science, Durham University, Durham, UK
| | - L J Ells
- School of Health and Social Care, Teesside University, Middlesbrough, UK
- FUSE, Centre for Translational Research in Public Health, North East England, UK
| |
Collapse
|
49
|
Brown TJ, Bota DA, Maher EA, Aregawi DG, Liau LM, Brown PD, Buckner JC, Weller M, Van Den Bent MJ, Berger MS, Glantz MJ. Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2057 Background: The optimal role of chemotherapy and radiation (RT) in adult low-grade glioma (LGG, WHO grade 1 & 2) is unclear. We conducted a systematic review and study-level meta-analysis of the literature on overall survival (OS) and progression free survival (PFS) in patients with LGG. Methods: Pubmed was queried with MeSH terms. All comparative studies of adults with newly diagnosed, supratentorial LGG were included. Comparisons of interest were OS and PFS at 2, 5, and 10 years in chemotherapy versus no chemotherapy and early RT versus delayed or no RT. Data were extracted from studies and synthesized with a random effects model. Quality of evidence was determined by American Academy of Neurology criteria and further analysis was performed, separating high quality (class I and II) from low quality (class III and IV) evidence. Numbers needed to treat (NNT) were determined from the risk difference. Results: 1531 articles were screened; 18 studies were included. Chemotherapy was not associated with a significant survival advantage compared to control. However, an analysis of high quality data revealed a survival advantage at 10 years associated with chemotherapy compared to control with NNT 5 (relative risk death chemo vs control 0.69 [0.56-0.86] p = 0.0006). Furthermore, NNT to prevent one progression with chemotherapy at 5 and 10 years was 6 and 3, respectively. Early RT was not associated with an OS advantage compared to control. However, early RT had progression benefit at all time points, with NNT of 10, 6, and 5 at 2, 5, and 10 years. Conclusions: Further study will be needed to confirm the optimal role of chemotherapy and RT. Caution must be used in interpretation as much of the literature consists of low-quality studies. [Table: see text]
Collapse
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | | | - Linda M. Liau
- University of California Los Angeles School of Medicine, Los Angeles, CA
| | | | | | - Michael Weller
- Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland
| | | | | | | |
Collapse
|
50
|
Brown TJ, Bota DA, Maher EA, Aregawi DG, Liau LM, Brown PD, Buckner JC, Weller M, Van Den Bent MJ, Berger MS, Glantz MJ. Association of aggressive resection with survival and progression-free survival in adult low-grade glioma: A systematic review and meta-analysis with numbers needed to treat. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2025 Background: Low-grade gliomas (LGG) account for 17-22% of all primary brain tumors. Optimal surgical management consists of optimum safe resection with the goal of complete resection. We performed a systematic review and meta-analysis to quantify the association of extent of resection with likelihood of survival, expressing our results in numbers needed to treat (NNT). Methods: A systematic review and study-level meta-analysis to determine the association of resection with overall survival and progression-free survival in newly diagnosed, supratentorial LGG in adults was performed by querying PubMed. Data were extracted to compare gross total resection (GTR) to subtotal resection (STR) and STR to biopsy (Bx) to determine relative risks (RR) of death and progression at 2, 5, and 10 years. Data were analyzed using a random effects model. NNT were calculated from significant comparisons and rounded up to the nearest whole number. Quality of evidence was determined by American Academy of Neurology criteria. Results: The systematic review resulted in 283 potential studies. Ultimately 29 studies were included in at least one comparison. There were no high quality (class I and II) or prospective studies discovered in the review. Comparing GTR to STR, RR with 95% confidence intervals (CI) of death at 2, 5, and 10 years, and NNT to avoid one death at 2, 5, and 10 years (GTR vs. STR) were 0.29 [0.17-0.52, p < 0.0001, NNT 17], 0.39 [0.29-0.51, p < 0.00001, NNT 6], and 0.50 [0.35-0.70, p < 0.0001 NNT 4]. RR and NNT for progression (GTR vs. STR) at 2, 5, and 10 years were 0.37 [0.24-0.57, p < 0.0001 NNT 7], 0.50 [0.39-0.64, p < 0.0001 NNT 4], and 0.67 [0.53-0.84, p = 0.0005 NNT 4]. Comparing STR to Bx, RR of death at 2, 5, and 10 years were 0.55 [0.34-0.88, p = 0.01 NNT 10], 0.9 [0.61-1.34], and 0.95 [0.73-1.23]. Conclusions: Increasing resection thresholds appear to be associated with improved overall and progression free survival, but the body of literature consists of low quality studies. Prospective studies are required to explore whether extent of resection matters or whether resectable tumors share a favorable biology associated with better outcome.
Collapse
Affiliation(s)
- Timothy J Brown
- The University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | | | - Linda M. Liau
- University of California Los Angeles School of Medicine, Los Angeles, CA
| | | | | | - Michael Weller
- Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland
| | | | | | | |
Collapse
|